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S U M M A R Y
Objective: To assess a new, fully-liquid, hexavalent DTaP–IPV–Hep B–PRP-T vaccine (diphtheria toxoid
(D), tetanus toxoid (T), acellular pertussis (aP), inactivated poliovirus (IPV), hepatitis B (Hep B), and
Haemophilus inﬂuenzae type b polysaccharide conjugated to tetanus protein (PRP-T) antigens) compared
to a licensed DTaP–IPV–Hep B//PRP-T vaccine following primary series co-administrationwith a 7-valent
pneumococcal conjugate vaccine (PCV7).
Methods: This was a randomized, phase III, observer-blind study in Thai infants (N = 412), who received
DTaP–IPV–Hep B–PRP-T or DTaP–IPV–Hep B//PRP-T at 2, 4, and 6 months of age, co-administered with
PCV7. All received Hep B at birth. Non-inferiority for Hep B 10 mIU/ml and PRP 0.15 mg/ml was
analyzed (DTaP–IPV–Hep B–PRP-T relative to DTaP–IPV–Hep B//PRP-T) at 1 month post-primary.
Seroprotection/seroconversion and geometric mean titers (GMTs) were analyzed descriptively for all
hexavalent components. Safety was evaluated from parental reports.
Results: Anti-Hep B and anti-PRP antibody seroprotection rates were high for DTaP–IPV–Hep B–PRP-T
(n = 189) and DTaP–IPV–Hep B//PRP-T (n = 190), and non-inferiority was demonstrated. Anti-D and anti-
T0.01 IU/ml, anti-polio types 1, 2, and 38 (1/dil), and anti-PT and anti-FHA seroconversion were high
and similar in each group. For DTaP–IPV–Hep B–PRP-T and DTaP–IPV–Hep B//PRP-T, anti-Hep B
100 mIU/ml was 98.4% and 99.5% (GMTs 2477 and 2442 mIU/ml), respectively; anti-PRP 1.0 mg/ml
was 85.2% and 71.1% (GMTs 5.07 and 2.41 mg/ml), respectively. Safety proﬁles were comparable. There
were no vaccine-related serious adverse events.
Conclusions: Following co-administrationwith PCV7 the investigational DTaP–IPV–Hep B–PRP-T vaccine
was safe and immunogenic. Non-inferiority to DTaP–IPV–Hep B//PRP-T was shown for Hep B and PRP.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The investigational DTaP–IPV–Hep B–PRP-T vaccine, Hexax-
imTM, is part of Sanoﬁ Pasteur’s AcXim family of pediatric
combination vaccines. This vaccine family is based on well-
established diphtheria toxoid (D), tetanus toxoid (T), acellular
(two-component) pertussis (aP), inactivated poliovirus (IPV), and§ Data presented at the 5th Asian Congress of Pediatric Infectious Diseases
(ACPID), Taipei, Taiwan, September 23–26, 2010.
* Corresponding author. Tel.: +33 0 4 37 37 58 53; fax: +33 0 4 37 37 78 88.
E-mail address: eduardo.santos-lima@sanoﬁpasteur.com (E. Santos-Lima).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.12.004Haemophilus inﬂuenzae type b polysaccharide conjugated to
tetanus protein (PRP-T) antigens. The IPV and PRP-T components
are World Health Organization (WHO) pre-qualiﬁed1 as stand-
alone vaccines (Imovax1 Polio and ActHib1, respectively), and the
AcXim family tetra- and pentavalent vaccines Tetraxim1/Tetra-
vac1 and Pentaxim1/Pentavac1 have been licensed and marketed
in more than 100 countries since 1997.2 The investigational
vaccine incorporates a new, Hansenula polymorpha-derived,
thimerosal-free hepatitis B (Hep B) component3,4 with the ﬁve
established valences in Pentaxim/Pentavac to create a new
hexavalent vaccine, DTaP–IPV–Hep B–PRP-T. This new investiga-
tional hexavalent vaccine is preservative-free, and its administra-
tion is facilitated by being fully liquid and in a mono-doseses. Published by Elsevier Ltd. All rights reserved.
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component administered as a standalone vaccine have been
evaluated successfully in previous investigations in South Ameri-
can adolescents,4 and the immunogenicity of each component of
the new hexavalent vaccine, incorporating the new Hep B antigen,
has been successfully evaluated in infants in Central America,
South America, and South Africa.5,6,7 Additionally, the effectiveness
of the two-component aP valence has been demonstrated by
pertussis surveillance in Sweden, Austria, and France.8,9,10,11,12
The combination of several antigens in a single vaccine has
myriad advantages for the vaccinee (e.g., a reduced number of
injections coupled with improved compliance to challenging
pediatric vaccination schedules and adequate disease protection),
the medical staff (e.g., a simpliﬁed, more manageable vaccination
calendar, saving time and resulting in fewer errors), and for society
as a whole (e.g., improved disease control resulting from improved
compliance, reduced direct and indirect costs compared to
standalone vaccine administration). Such pediatric combination
vaccines have become the standard of care in many countries, and
their routine use has had an enormous impact in reducing the
incidence of childhood diseases.13,14 However, regional disparities
remain, e.g. regarding the use of aP versuswhole cell pertussis (wP)
vaccines, or the inactivated poliovirus vaccine (IPV) versus the oral
poliovirus vaccine (OPV).
Pneumococcal conjugate vaccines are routinely co-adminis-
tered with pediatric combination vaccines, having been widely
integrated into vaccination schedules in many countries, including
Thailand. This clinical trial was therefore conducted to investigate
the possible effect of the co-administration of a 7-valent
pneumococcal conjugate vaccine (PCV-7; Prevnar1) on the
immunogenicity and safety proﬁle of the new pediatric hexavalent
vaccine. It has previously been reported by some authors that the
immunogenicity of the Hep B and PRP-T components in some
multivalent combination vaccines may be inﬂuenced by concomi-
tant administration of pneumococcal vaccine.15,16 We therefore
focused our statistical analysis on the performance of these two
components. In addition, as the Hep B antigen is the new
component of our hexavalent vaccine, we included the assessment
of its immunogenicity as a primary objective of this study. The
response to the remaining antigens was analyzed descriptively.
Immunogenicity and safety datawere compared to those following
the co-administration of a licensed hexavalent comparator
(Infanrix hexa1) with Prevnar. We did not measure the immune
response to Prevnar antigens, as this has previously been shown
not to be affected by co-administration with multivalent IPV–aP-
containing vaccines,17 and also because we would have required a
signiﬁcantly larger blood sample to perform all of the serological
analyses, which would have presented ethical problems in this
neonatal population.
2. Materials and methods
2.1. Study design and participants
This phase III, observer-blind, randomized, controlled four-
centre trial included healthy 2-month-old infants, born at full term
(37 weeks of pregnancy) with birth weight 2.5 kg (Clinical-
Trials.gov identiﬁer: NCT00401531). All participants had received
a hepatitis B vaccine at birth according to the Thai national
standards at the time of the study and to comply with the Thai
Standard Vaccination Schedule.18 Participants were excluded for
any of the following reasons: participation in another clinical trial
in the 4 weeks prior to the ﬁrst vaccination in our trial, or planned
participation in another clinical trial during the planned period of
participation in our trial; hypersensitivity to any of the vaccine
components; congenital or acquired immunodeﬁciency; chronicillness that could interfere with conduct or completion of the trial;
receipt of blood-derived products since birth; any vaccination in
the 4 weeks prior to the ﬁrst vaccination or any planned
vaccination during the trial (other than trial vaccinations); history
of, or previous vaccination against, pertussis, tetanus, diphtheria,
polio, H. inﬂuenzae type b (Hib), hepatitis B, or Streptococcus
pneumoniae infection; known personal or maternal history of
human immunodeﬁciency virus (HIV), hepatitis B (hepatitis B
surface antigen (HBsAg) carrier) or hepatitis C seropositivity;
bleeding disorder contraindicating intramuscular injection; histo-
ry of seizures; rectal equivalent temperature 38 8C on the day of
inclusion.
The protocol and informed consent form and amendments
were approved by the independent ethics committees of the
four study centers in Thailand (Khon Kaen University, Chula-
longkorn Hospital, Ramathibodi Hospital, and Siriraj Hospital).
The trial was done in accordance with the recommendations of
the Declaration of Helsinki (Edinburgh revision, October 2000)
and International Conference on Harmonisation (ICH) Good
Clinical Practice (GCP), and with applicable national and local
requirements.
One of the participant’s parents or a legally acceptable
representative gave written informed consent before the partici-
pant was included in the trial, according to local procedures. If
illiterate, an independentwitness additionally signed the informed
consent form to attest that its information had been accurately
explained to and understood by the participant’s parent(s)/legally
acceptable representative(s).
Following the veriﬁcation of inclusion/exclusion criteria, 412
participants were randomized in a 1:1 ratio to receive either the
investigational DTaP–IPV–Hep B–PRP-T vaccine (group 1) or
DTaP–IPV–Hep B//PRP-T (group 2) at 2, 4, and 6 months of age.
All participants received co-administration of PCV7 at 2, 4, and 6
months of age and Hep B at birth. The sponsor’s biostatistics
department created the randomization list.
2.2. Vaccines and vaccine administration
The investigational DTaP–IPV–Hep B–PRP-T vaccine (batch
number S4106; Hexaxim)wasmanufactured by Sanoﬁ Pasteur and
supplied in pre-ﬁlled 0.5-ml syringes that were shaken gently
before injection. The needle sizewas 25G/16 mm. Each 0.5-ml dose
contained 20 IU (30 limit of ﬂocculation (Lf)) diphtheria toxoid,
40 IU (10 Lf) tetanus toxoid, 25 mg pertussis toxoid (PT), 25mg
ﬁlamentous hemagglutinin (FHA), 40, 8, and 32 D-antigen units of
IPV types 1, 2, and 3, respectively, 12 mg of H. inﬂuenzae type b
polysaccharide conjugated to tetanus toxoid, 10 mg HBsAg, and
0.6 mg aluminum hydroxide.
The control DTaP–IPV–Hep B//PRP-T vaccine (batch number
A21CA130A; Infanrix hexa)wasmanufactured byGlaxoSmithKline
Biologicals and supplied as two separate components (a DTaP–Hep
B–IPV suspension in a pre-ﬁlled syringe and PRP-T as a white pellet
in a glass vial) that were reconstituted as a 0.5-ml dose
immediately prior to injection. The needle size was 25G/25 mm.
Each dose contained 30 IU of diphtheria toxoid, 40 IU tetanus
toxoid, 25 mg PT, 25 mg FHA, 8mg pertactin, 40, 8, and 32 D-
antigen units of IPV types 1, 2, and 3, respectively, 10 mg of H.
inﬂuenzae type b polysaccharide conjugated to 20–40 mg tetanus
toxoid, 10 mg HBsAg; the PRP-T and HBsAg were adsorbed on
1.45 mg aluminum phosphate and the D, T, PT, FHA, and pertactin
were adsorbed on 0.95 mg hydrated aluminum oxide.
The PCV7 vaccine, Prevnar (batch number 20882) was
manufactured byWyeth and supplied in pre-ﬁlled 0.5-ml syringes.
Each 0.5-ml dose contained 2mg pneumococcal polysaccharide
serotypes 4, 9 V, 14, 18C, 19F, and 23F and 4mg pneumococcal
polysaccharide serotype 6B; each serotype was conjugated to a
P. Kosalaraksa et al. / International Journal of Infectious Diseases 15 (2011) e249–e256 e251CRM197 carrier protein and adsorbed on 0.5 mg aluminum
phosphate.
The DTaP–IPV–Hep B–PRP-T and DTaP–IPV–Hep B//PRP-T
vaccines were administered intramuscularly into the anterolateral
aspect of the right thigh, and PCV7 was administered intramuscu-
larly into the anterolateral aspect of the left thigh. Administration
guidelines were provided for each vaccine.
A commercially available hepatitis B vaccine was administered
at birth in accordance with the national immunization calendar in
Thailand, and outside the scope of this trial.
2.3. Serology
A 3-ml blood sample was taken at 2 months of age (i.e., prior to
the ﬁrst primary series vaccination) for determination of anti-PT
and anti-FHA antibody concentrations; a 5-ml sample was taken at
7 months of age (i.e., 1 month after the third vaccination) for
assessment of antibodies to all antigens.
Serological analyses were done at the Sanoﬁ Pasteur Global
Clinical Immunology Laboratory in the USA. Anti-poliovirus
antibody titers were measured by seroneutralization. Anti-D,
anti-T, anti-PT, and anti-FHA antibody concentrations were
measured by enzyme-linked immunosorbent assay (ELISA).
Antibody to hepatitis B surface antigen (anti-HBs) concentrations
weremeasured using the commercially-available VITROS anti-HBs
assay (Ortho-Clinical Diagnostics, Inc, Rochester, NY USA). Anti-
PRP antibody concentrations were measured by a Farr-type
radioimmunoassay (RIA).
2.4. Reactogenicity and safety
For routine evaluation of reactogenicity and safety, each
participant was observed by the investigator for 30 min after
each vaccination to monitor for any immediate adverse events. In
addition, for pre-deﬁned (solicited) injection site (pain, erythema,
and swelling) and systemic (pyrexia, vomiting, crying, somnolence,
anorexia, and irritability) reactions, daily intensity/measurement
was recorded by the parent(s)/legally responsible representative
using diary cards for 7 days following each vaccination (Note: All
solicited events were considered to be related to the vaccination,
and any event related to vaccination was termed a ‘reaction’). In
addition, the parent(s)/legally responsible representative recordedTable 1
Seroprotection/seroconversion rates at 1month after the three-dose primary vaccination
set)a
Antibody Threshold G
Primary endpoints Anti-Hep B 10mIU/mld 9
Anti-PRP 0.15mg/mld 9
Secondary endpoints Anti-Hep B 100 mIU/ml 9
Anti-PRP 1.0mg/ml 8
Anti-D 0.01 IU/ml 9
0.1 IU/ml 7
1.0 IU/ml 2
Anti-T 0.01 IU/ml 1
0.1 IU/ml 1
1.0 IU/ml 7
Anti-polio 1 8 (1/dil) 1
Anti-polio 2 8 (1/dil) 1
Anti-polio 3 8 (1/dil) 1
Anti-PT 4-fold increasee 9
Anti-FHA 4-fold increasee 9
Hep B, hepatitis B; PRP, polyribosyl ribitol phosphate; D, diphtheria; T, tetanus; polio 1,
toxoid; FHA, ﬁlamentous hemagglutinin; NC, not calculated (as secondary assessment
aData are % participants (95% conﬁdence interval), calculated according to the subjects a
administered with PCV7); n is the number of subjects analyzed according to the per
administered with PCV7); n is the number of subjects analyzed according to the per-proto
groups 1 and 2).
eCompared to pre-ﬁrst primary series dose data.the start/stop date and intensity/measurement of any non-
solicited events to the next visit. All non-solicited injection site
events were considered to be related to the vaccination and so
were recorded as injection site reactions; the relationship to the
vaccination for non-solicited systemic events was assessed by the
investigators. Each adverse event was categorized as grade 1
(mild), grade 2 (moderate), or grade 3 (severe) by the investigators.
Grades 1, 2, and 3 pain were deﬁned as ‘minor reaction when
injection site is touched’, ‘cries and protests when injection site is
touched’, and ‘cries when injected limb is moved or the movement
of the injected limb is reduced’, respectively. For erythema and
swelling, a diameter of < 2.5 cm was assessed as grade 1, from 2.5
to < 5 cm as grade 2, and5 cm as grade 3. Grades 1, 2, and 3 fever
were deﬁned as rectal temperature37.4 8C to 37.9 8C,38.0 8C to
38.9 8C, and39.0 8C, respectively. Other systemic symptomswere
deﬁned as: vomiting (grade 1–grade 2, 1 to 5 episodes/day; grade
3, 6 episodes/day), abnormal crying (grade 1–grade 2, 3 h;
grade 3, >3 h), drowsiness (grade 1–grade 2, unusually sleepy;
grade 3, sleepymost of the time), loss of appetite (grade 1–grade 2,
missed 1 to 2 meals; grade 3, missed 3 meals), and irritability
(grade 1–grade 2, easily consolable or needs increased attention;
grade 3, inconsolable). For cultural and compliance reasons,
axillary rather than rectal temperature was measured; the
biostatistician at Sanoﬁ Pasteur subsequently converted this to a
rectal equivalent value by adding 0.6 8C.
Serious adverse events (SAEs) were collected throughout the
study, until 6 months after the ﬁnal primary series vaccination.
2.5. Statistical analyses
The primary objective of the trial was to assess the Hep B and
PRP seroprotection, based on respective thresholds of10 mIU/ml
and 0.15mg/ml at 1 month after the three-dose primary
vaccination series, and to demonstrate non-inferiority of the
investigational DTaP–IPV–Hep B–PRP-T vaccine to the licensed
DTaP–IPV–Hep B//PRP-T comparator.
Secondary objectives included the description of the immuno-
genicity of all antigens for the hexavalent vaccines and the
description of reactogenicity and safety proﬁles in each group.
Well-established correlates of seroprotection were used for D,
T, polio types 1, 2, and 3, Hib, and Hep B (shown in Table 1). Since
there are no universally accepted correlates of protection forseries, including statistical analysis for the primary objective (per-protocol analysis
roup 1 (n=189)b Group 2 (n=190)c Group 1  group 2
9.5 (97.1; 100.0) 99.5 (97.1; 100.0) 0.01 (2.46; 2.43)
7.9 (94.7; 99.4) 96.3 (92.6; 98.5) 1.57 (2.15; 5.51)
8.4 (95.4; 99.7) 99.5 (97.1; 100.0) NC
5.2 (79.3; 89.9) 71.1 (64.0; 77.4) NC
7.4 (93.9; 99.1) 100.0 (98.1; 100.0) NC
5.7 (68.9; 81.6) 66.3 (59.1; 73.0) NC
6.5 (20.3; 33.3) 12.1 (7.8; 17.6) NC
00.0 (98.1; 100.0) 100.0 (98.1; 100.0) NC
00.0 (98.1; 100.0) 100.0 (98.1; 100.0) NC
0.9 (63.9; 77.3) 87.9 (82.4; 92.2) NC
00.0 (98.0; 100.0) 100.0 (98.0; 100.0) NC
00.0 (98.0; 100.0) 100.0 (98.0; 100.0) NC
00.0 (98.0; 100.0) 99.5 (97.0; 100.0) NC
3.7 (89.2; 96.7) 93.7 (89.2; 96.7) NC
4.7 (90.4; 97.4) 95.2 (91.1; 97.8) NC
poliovirus type 1; polio 2, poliovirus type 2; polio 3, poliovirus type 3; PT, pertussis
criteria).
vailable for the endpoint. bGroup 1: DTaP–IPV–Hep B–PRP-T at 2, 4, 6 months (co-
-protocol analysis set. cGroup 2: DTaP–IPV–Hep B//PRP-T at 2, 4, 6 months (co-
col analysis set. dPrimary endpoint (with statistical test for non-inferiority between
P. Kosalaraksa et al. / International Journal of Infectious Diseases 15 (2011) e249–e256e252pertussis (PT and FHA antigens), the seroconversion rate for these
antigens was pre-deﬁned as a 4-fold increase from baseline in
anti-PT and anti-FHA antibody titers (ELISA units (EU)/ml);19 for
this reason baseline (prior to the ﬁrst vaccination) samples were
taken for PT and FHA only, and all valences for the hexavalent
vaccines were assessed at 1 month after the third vaccination.
The non-inferiority comparison was based on the difference
(group 1minus group 2) in seroprotection rate for Hep B (10mIU/
ml) and PRP (0.15mg/ml) antibodies, with non-inferiority being
concluded if the lower bound of the two-sided 95% conﬁdence
interval (CI) of the difference was above 10%. The 95% CI was
calculated based on the Wilson score method without continuity
correction, as described by Newcombe.20
Secondary immunogenicity endpoints were descriptive analy-
ses of antibody concentrations/titers and seroprotection/serocon-
version at pre-deﬁned thresholds (see Table 1) for all valences in
each group. In addition, safety was analyzed as a secondary
objective for each group (percentage of participants with a
particular event and associated 95% CI calculated using the exact
binomial Clopper–Pearson method, quoted by Newcombe21).
Seroprotection/seroconversion rates were calculated with their
95% CIs using the exact binomial method.21 Geometric mean titers
(GMTs)/geometric mean concentrations (GMCs) were calculatedN=412 
Participants rando
(all received hepatitis B va
N=206
Group 1
DTaP-IPV-Hep B-PRP-T at 2, 4, 6 months
(co-administered with Prevnar™)
ITT analysis set
N=197 completed
N=9 discontinued
Non-serious AE (2)
Non-compliance (3)
Lost to follow-up (1)
Voluntary withdrawal not for adverse 
event (3):
-relocation [2]
-paternal concern over vaccine [1]
N=189
PP analysis set
Reasons for exlusion from PP analysis set*:
 Blood sample post-3rd dose not taken or titers not 
available (9)
 Received at least one unplanned vaccine (2)
 Not received three doses (8)
 Time interval between 1st/2nd or 2nd/3rd dose or 3rd 
dose/2nd blood sample outside limit (9)
Figure 1. Participant disposition and analysis sets (N, number; PP, per protocol;with their 95% CIs using the normal approximation method.
Reverse cumulative distribution curves (RCDCs) are presented for
the primary objective antigens (Hep B and PRP).
It was planned to include a total of 412 participants in the study,
randomly allocated to group 1 or group 2, in order to provide data
from 350 evaluable participants following an anticipated drop-out
rate of 15% (62 participants). This sample size was calculated using
the Farrington and Manning formula and was based on a type 1
error of 2.5% (one-sided hypothesis) to provide an overall power of
90% for the primary objective.22
The intent-to-treat (ITT) analysis set comprised all partici-
pants who received at least one dose of vaccine, analyzed by
randomization group. The per-protocol (PP) analysis set
comprised ITT participants who received the three doses of
primary series with no protocol deviations. The safety analysis
set comprised participants who received at least one dose of
trial vaccine, analyzed by vaccine received. The primary
hypothesis of non-inferiority for group 1 minus group 2
immunogenicity was tested on the PP analysis set and conﬁrmed
using the ITT analysis set. The safety analysis set was used for
the safety analysis.
All analyses except the SAE analysis were done using SAS
software version 9.1 (SAS Institute, Cary, NC, USA).mized
ccination at birth)
N=206
Group 2
Infanrix hexa™ at 2, 4, 6 months
(co-administered with Prevnar™)
ITT analysis set
N=196 completed
N=10 discontinued
Non-compliance (7)
Lost to follow-up (1)
Voluntary withdrawal not for adverse 
event (2)
-relocation [1]
-transportation problem [1]
N=190
PP analysis set
Reasons for exlusion from PP analysis set*:
 At least one inclusion criteria not met (1)
 Blood sample post-3rd dose not taken or titers not 
available (10)
 Received at least one unplanned vaccine (6)
 Not received three doses (9)
 Time interval between 2nd/3rd dose or 3rd dose/2nd 
blood sample outside limit (5)
ITT, intent-to-treat; *there may be more than one reason per participant).
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3.1. Participants studied
A total of 412 participants were included in the trial, with 206
participants being randomized to each group; overall participant
disposition is summarized in Figure 1. Nine (4.4%) participants in
group 1 and 10 (4.9%) in group 2 did not complete the trial; 17
(8.3%) participants in group 1 and 16 (7.8%) in group 2 were
excluded from the PP analysis set (see Figure 1 for reasons for non-
completion of the trial and exclusion from the PP analysis set). The
PP analysis set therefore included 189 and 190 participants in
groups 1 and 2, respectively, satisfying the sample size power
calculation for the primary objective.
The trial took place between October 2006 andNovember 2007.
Demographic characteristics were similar in each group.
3.2. Immunogenicity
Seroprotection/seroconversion rates (Table 1) and GMCs/GMTs
(Table 2) for the PP population were high for both groups. For anti-
Hep B, 99.5% of participants had a concentration 10 mIU/ml in
each group, and 97.9% of participants in group 1 and 96.3% in group
2 had an anti-PRP concentration 0.15mg/ml. The statistical
comparison showed non-inferiority of the investigational DTaP–
IPV–Hep B–PRP-T vaccine, with the lower bound of the 95% CI of
the difference between the seroprotection rates (group 1 minus
group 2) being above 10% (2.46 for anti-Hep B and 2.15 for
anti-PRP).
Regarding the secondary endpoints, and based on non-over-
lapping 95% CIs, the only differences based on thresholds/
seroconversion (Table 1) were the percentage of participants with
anti-PRP 1.0 mg/ml and anti-D 1.0 IU/ml (greater for the
investigational DTaP–IPV–Hep B–PRP-T vaccine: 85.2% vs. 71.1%
for anti-PRP and 26.5% vs. 12.1% for anti-D) and anti-T 1.0 IU/ml
(greater for the comparator: 87.9% vs. 70.9%). For GMTs/GMCs
(Table 2), anti-PRP and anti-FHA were higher for the investiga-
tional DTaP–IPV–Hep B–PRP-T vaccine, and anti-T, anti-polio 1, 2,
and 3, and anti-PT were higher for the comparator. The GMTs for
anti-Hep B and anti-D were similar in each group. The RCDCs for
each antigen are presented in Figure 2.
The results for the ITT population (not presented) supported
those for the PP population.Table 2
Geometric mean titers/concentrations at 1 month after the three-dose primary
vaccination series (per-protocol analysis set)a
Antibody Group 1 (n=189)b Group 2 (n=190)c
Anti-Hep B (mIU/ml) 2477 (2044; 3002) 2442 (2096; 2844)
Anti-PRP (mg/ml) 5.07 (4.05; 6.33) 2.41 (1.95; 2.98)
Anti-D (IU/ml) 0.297 (0.241; 0.367) 0.209 (0.177; 0.247)
Anti-T (IU/ml) 1.38 (1.25; 1.52) 1.83 (1.69; 1.97)
Anti-polio 1 (1/dil) 765 (649; 902) 1566 (1326; 1850)
Anti-polio 2 (1/dil) 1489 (1259; 1761) 2277 (1905; 2723)
Anti-polio 3 (1/dil) 837 (695; 1007) 2029 (1646; 2502)
Anti-PT (EU/ml) 168 (154; 183) 200 (185; 216)
Anti-FHA (EU/ml) 148 (136; 162) 123 (113; 132)
Hep B, hepatitis B; PRP, polyribosyl ribitol phosphate; D, diphtheria; T, tetanus;
polio 1, poliovirus type 1; polio 2, poliovirus type 2; polio 3, poliovirus type 3; PT,
pertussis toxoid; FHA, ﬁlamentous hemagglutinin.
aData are geometric mean concentrations for anti-Hep B, anti-PRP, anti-D, anti-T,
anti-PT and anti-FHA and geometricmean titers for anti-polio types 1, 2, and 3, with
95% conﬁdence intervals. bGroup 1: DTaP–IPV–Hep B–PRP-T at 2, 4, 6 months (co-
administeredwith PCV7); n is the number of subjects analyzed according to the per-
protocol analysis set. cGroup 2: DTaP–IPV–Hep B//PRP-T at 2, 4, 6 months (co-
administeredwith PCV7); n is the number of subjects analyzed according to the per-
protocol analysis set.3.3. Safety and tolerability
No immediate adverse events (i.e., those occurring in the
30 min after vaccination) were reported in either group. Solicited
injection site and systemic reactions (all grades and grade 3) are
summarized in Table 3. Overall the frequency of solicited reactions
was similar between groups and there was no difference between
groups in the frequency of grade 3 reactions for any solicited
injection site or systemic symptom. The frequency of solicited
injection site swelling (group 1: 41.3% and group 2: 31.6%) and
pyrexia (group 1: 74.1% and group 2: 63.6%) was numerically
higher in group 1 compared to group 2. For pyrexia, which was
10.5%more frequent in group 1, a post-hoc analysis was performed
based on the recommendations of the Brighton Collaboration,23,24
which recommends no conversion of oral or axillary to rectal-
equivalent temperature prior to analysis. The results of this post-
hoc analysis showed that there was no difference between groups
in the frequency of either overall pyrexia (38.0%, 95% CI 31.4–45.1
for participants in group 1 and 35.4%, 95% CI 28.9–42.4 for those in
group 2) or grade 3 pyrexia (1.0%, 95% CI 0.1–3.5 for participants in
group 1 and 1.9%, 95% CI 0.5–4.9 for those in group 2).
The frequency of unsolicited events (systemic and injection site
combined)was similar in each group (66.0% in group 1 and 62.1% in
group 2), with few being considered to be related to the
vaccination (2.4% of participants with unsolicited reactions in
group 1 and 3.9% in group 2).
Six participants (2.9%) in group 1 and eight (3.9%) in group 2
experienced an SAE in the period up to 1 month after the third
vaccination, with a further 13 (6.3%) and four (1.9%) participants,
respectively, reporting an SAE from 1 month to 6 months after the
third vaccination. These were common childhood symptoms and
none was considered by the investigators to be related to the
vaccination. No participant died during the study and none was
withdrawn due to an SAE.
4. Discussion
In our trial we have demonstrated that the Hep B and PRP
responses in terms of the percentage of participants with a
concentration10mIU/ml or0.15mg/ml, respectively, following
co-administration of DTaP–IPV–Hep B–PRP-T with the pneumo-
coccal conjugate vaccine, were non-inferior to those observed for
the hexavalent comparator. Furthermore, these responses were
comparable to historical control data following administration of
the investigational vaccine (at 2, 4, and 6 months of age in
Argentina)7 or the control vaccine (at 2, 3, and 4 months of age in
Germany)25 alone. Hep B was not administered at birth in the
earlier trials and this is reﬂected by higher GMCs for Hep B in our
trial, which included a birth dose of Hep B. This effect of the birth
dose of Hep B to augment the GMC response would be expected
based on previous studies.26 However, it should be noted that the
Hep B response in terms of the percentage of participants with a
concentration 10 mIU/ml (the accepted correlate for seroprotec-
tion) is consistently high in both our study and the previous studies
following administration of the investigational vaccine, irrespec-
tive of whether Hep B is administered at birth or not.6
For the remaining antigens and their associated surrogate
thresholds of seroprotection (and seroconversion for PT and FHA,
there being no accepted correlate of seroprotection for these
antigens), the immune response was generally high and similar for
the two groups, and again these responses were comparable to
historical data.7,15,25 Some descriptive differences, however, were
noted between groups. Notably, the anti-PRP response was higher
for the investigational vaccine in terms of the percentage of
participants with a titer 1.0 mg/ml; this effect is reﬂected in the
higher anti-PRP GMC for the investigational vaccine group. The
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Figure 2. Reverse cumulative distribution curves (per-protocol analysis set): (a) anti-Hep B; (b) anti-PRP; (c) anti-D; (d) anti-T; (e) anti-polio 1; (f) anti-polio 2; (g) anti-polio
3; (h) anti-PT; (i) anti-FHA. Group 1: DTaP–IPV–Hep B–PRP-T at 2, 4, 6 months (co-administered with PCV7); group 2: DTaP–IPV–Hep B//PRP-T at 2, 4, 6 months (co-
administered with PCV7).
P. Kosalaraksa et al. / International Journal of Infectious Diseases 15 (2011) e249–e256e254observed difference in GMTs for the polio antigens is not
reﬂected by a difference in the percentage of participants with a
titer 8 (1/dil).
Overall, there were no marked differences in safety proﬁle
between participants who received the investigational vaccine and
those who received the comparator vaccine, and the clinical proﬁle
of the two groups can be considered similar. Furthermore, the
addition of the birth dose of Hep B had no effect on the
reactogenicity of the investigational vaccine, as expected basedon previous studies.26 Although the frequency of pyrexia was
higher in the investigational vaccine group, an extra, post-hoc,
analysis based on the Brighton Collaboration methodology,23,24
with no conversion to rectal-equivalent temperature, showed no
difference in the frequency of pyrexia between the two groups, and
the anti-pyretic use was similar in each group. Since the
completion of our trial, Sanoﬁ Pasteur has adopted the recom-
mendations of the Brighton Collaboration to accord with the
recommendations of regulatory authorities such as the US Food
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Figure 2. (Continued).
Table 3
Solicited injection site and systemic adverse reactions occurringwithin 8 days (days
0–7) after any dose of vaccine (safety analysis set)
Reaction Severity Group 1 (n=206)a Group 2 (n=206)b
Injection site reactions
Pain Any 87.8 (82.5; 92.0) 80.6 (74.5; 85.8)
Grade 3 9.8 (6.1; 14.7) 5.8 (3.0; 10.0)
Erythema Any 58.7 (51.7; 65.5) 55.3 (48.3; 62.3)
Grade 3 1.5 (0.3; 4.2) 1.0 (0.1; 3.5)
Swelling Any 41.3 (34.5; 48.3) 31.6 (25.3; 38.4)
Grade 3 0.5 (0.0; 2.7) 0.5 (0.0; 2.7)
Systemic reactions
Pyrexiac Any 74.1 (67.6; 80.0) 63.6 (56.6; 70.2)
Grade 3 2.9 (1.1; 6.3) 3.4 (1.4; 6.9)
Vomiting Any 37.6 (30.9; 44.6) 39.8 (33.1; 46.8)
Grade 3 0.5 (0.0; 2.7) 1.5 (0.3; 4.2)
Crying Any 81.1 (75.0; 86.2) 74.3 (67.7; 80.1)
Grade 3 3.4 (1.4; 6.9) 2.4 (0.8; 5.6)
Somnolence Any 68.8 (62.0; 75.1) 60.7 (53.7; 67.4)
Grade 3 2.0 (0.5; 4.9) 0.0 (0.0; 1.8)
Anorexia Any 44.4 (37.5; 51.5) 40.3 (33.5; 47.3)
Grade 3 0.0 (0.0; 1.8) 0.0 (0.0; 1.8)
Irritability Any 79.0 (72.8; 84.4) 77.2 (70.8; 82.7)
Grade 3 2.0 (0.5; 4.9) 2.9 (1.1; 6.2)
Data are % participants (95% conﬁdence interval). aGroup 1: DTaP–IPV–Hep B–PRP-
T at 2, 4, 6months (co-administeredwith PCV7). bGroup 2: DTaP–IPV–Hep B//PRP-T
at 2, 4, 6 months (co-administered with PCV7). cData presented are rectal
equivalent (see text for details).
P. Kosalaraksa et al. / International Journal of Infectious Diseases 15 (2011) e249–e256 e255and Drug Administration (FDA), and no longer performs conver-
sion calculations to obtain estimates of rectal-equivalent temper-
ature. Since the relationships between oral, axillary and rectal
temperatures are not consistent, simple conversion calculations
can provide misleading conclusions and so are best
avoided;23,27,28,29,30 it is for this reason that we conducted our
post-hoc analysis.
Overall, the immunogenicity and safety proﬁles of the new,
fully-liquid investigational hexavalent vaccine were good and
similar to those for the licensed hexavalent comparator following
co-administration with a PCV7 vaccine. These ﬁndings reﬂect the
anticipated proﬁles based on previous data.2,5,7,25,31,32 Our data
support the co-administration of the new hexavalent investiga-
tional vaccine with multivalent pneumococcal conjugate vaccines,
as strong immunogenicity for each of the hexavalent vaccine
components and a good safety proﬁle are demonstrated. As such,
the introduction of the new hexavalent vaccine into national
vaccination schedules would be facilitated and the required
number of clinic visits would not have to be increased, helping
to promote compliance to increasingly challenging pediatric
vaccination schedules.
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